Aktis Oncology announced first-in-human clinical imaging and dosimetry data for AKY-2519, a targeted radiopharmaceutical for B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer (mCRPC). The data showed strong tumor uptake and limited exposure to normal tissues, suggesting a favorable safety and efficacy profile compared to existing treatments. These results support ongoing Phase 1b trials in mCRPC and other solid tumors, with preliminary data expected in 2027. The findings will be presented at the 2026 ASCO Annual Meeting, highlighting AKY-2519's potential as a new therapeutic option for multiple cancer types.
Valneva declared its shares and voting rights status as of May 31, 2026, reporting 189,771,237 ordinary shares and a total of 204,238,965 exercisable voting rights after accounting for double voting rights on some shares. This update is important for...
Valneva announced an update on its share capital and voting rights as of May 31, 2026. The company reported a total of 189,771,237 ordinary shares with a nominal value of €0.15 each, and a total of 204,363,287 voting rights including suspended rights...
Integrated Quantum Technologies introduced VEIL™, a privacy-focused tool integrated into Snowflake's AI Data Cloud, which removes personally identifiable information (PII) from data before it is used in AI and machine learning models. This approach a...
Bluejay Diagnostics announced a private placement to raise up to $23.6 million, including $8.5 million upfront, to extend its cash runway into early 2027. The funds will support FDA submission and commercialization of its rapid sepsis testing system,...
Ed Yardeni, president of Yardeni Research, forecasts the Federal Reserve will raise interest rates at its July 29 meeting, a view that contrasts with the market's low expectations for a rate hike this summer. Yardeni cites a resilient economy, strong...
